AKCA News and Press, Akcea Therapeutics Inc. From 08/04/20

Akcea Therapeutics, Inc. (AKCA) Q2 2020 Earnings Conference Call August 4, 2020 16:30 ET Company Participants Angelyn Lowe - Executive Director, Corporate Communications & Investor Relations Damien McDevitt - Director & Chief Executive Officer Kyle Jenne - Chief Commercia...

Akcea Therapeutics (NASDAQ: AKCA ) : Q2 GAAP EPS of -$0.49 misses by $0.14 . More news on: Akcea Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

BOSTON , Aug. 4, 2020 /PRNewswire/ -- Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., focused on developing and commercializing medicines to treat patients with serious and rare diseases, today reported financial results for the sec...

BOSTON , July 22, 2020 /PRNewswire/ -- Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., today announced that the Main Association of Austrian Social Security Institutions (Dachverband der Österreichischen Sozialversicherungstr&#...

BOSTON , July 21, 2020 /PRNewswire/ -- Akcea Therapeutics, Inc. (NASDAQ:AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., announced today that it will host a live webcast on Tuesday, August 4 at 4:30 p.m. Eastern Time to discuss its second quarter 2020 financial res...

BOSTON , July 20, 2020 /PRNewswire/ -- Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., today announced that Christophe Hotermans, M.D., Ph.D., has joined the company as senior vice president of global medical affairs where he will lead a...

BOSTON , July 9, 2020 /PRNewswire/ -- Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., today announced that William Andrews , MD, FACP, has joined the company as chief medical officer (CMO), effective immediately. Dr. Andrews will l...

Last year I created a public screen on Portfolio123, a web-based subscription service that allows you to backtest screens and ranking systems. It invests in companies in the Russell 3000 that spend heavily on R&D. There were four rules in the screen, but the most important were these: ...

Gainers:  AKRO +33.8% . ETNB +21.1% . FDX +8.9% . AKCA +5.8% . UPS +5.0% . More news on: Akero Therapeutics, Inc., 89bio, Inc., FedEx Corporation, Stocks on the move, , Read more ...

BOSTON , June 17, 2020 /PRNewswire/ -- Akcea Therapeutics, Inc. (NASDAQ:AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., focused on developing and commercializing drugs to treat patients with serious and rare diseases, today announced that Damien McDevitt , chief ex...